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ABSTRACT: 
A variety of Ruthenium complexes possessing terpyridine complexes as ligands in their 
coordination sphere have been investigated extensively as DNA  photo nucleases in vitro(1,2). 
This work has led to the realization that compounds of Ruthenium bind to DNA purines and that 
the interactions are of an unprecedented bridging variety. Owing to the molar absorptivity of 
these complexes in the visible region, direct cleavage of duplex DNA by these complexes 
requires irradiation in the range of 400-500 nm. 
       Although the observation of DNA photo cleavage in vitro makes these systems good 
candidates for further investigation, it does not provide any information on whether the 
compounds would enter cells in vivo, cause cellular damage or death, or be able to penetrate the 
nucleus to affect DNA photo cleavage. In the present study, we explore the DNA photo cleavage 
using gel electrophoresis, cytotoxicity, photocytotoxicity and nuclear DNA damage by the 
Ruthenium compounds, which were recently shown to possess an emissive, pH- dependent 
ligand centered excited state. 
INTRODUCTION: 
Skin cancer is the most common form of cancer in the United States. More than 3.5 million cases 
in two million people are diagnosed annually3. The incidence of many common cancers is 
falling, but the incidence of melanoma continues to rise significantly, at a rate faster than that of 
any of the seven most common cancers4. According to the U.S. Department of Health and 
Human Services, Ultraviolet radiation is a proven carcinogenic to humans. Frequent tanners 
using new high-pressure sunlamps may receive as much as 12 times the annual UVA dose 
compared to the dose they receive from sun exposure5. UV light (200 – 300 nm) causes 
exogenous, irreversible damage to the DNA. UV-B radiation causes cross-linking of adjacent 
cytosine and thymine bases creating pyrimidine dimers. This is called direct DNA damage. UV-
A light results in the formation of free radicals. The damage caused by free radicals is called 
indirect DNA damage. 
 
If the doctor suspects that a spot on the skin is melanoma, the patient will need to have a biopsy. 
In this procedure, the doctor tries to remove all of the suspicious-looking growth. This is an 
excisional biopsy. If the growth is too large to be removed entirely, the doctor removes a sample 
of the tissue. The doctor will never "shave off" or cauterize a growth that might be melanoma. 
This might cause metastasis of the cancer. Some cancer cells acquire the ability to penetrate the 
walls of lymphatic and/or blood vessels, after which they are able to circulate through the 
bloodstream (circulating tumor cells) to other sites and tissues in the body. After the tumor cells 
come to rest at another site, they re-penetrate through the vessel or walls, continue to multiply, 
and eventually another clinically detectable tumor is formed. This new tumor is known as a 
metastatic or secondary tumor. If the cancer spreads to other tissues and organs, it may decrease 
a patient's likelihood of survival. At present, the treatments available for skin cancer are Surgery, 
Chemotherapy, Biological therapy, Radiation therapy and Photodynamic therapy. Of these, 
surgery and chemotherapy are conventional, painful and have a large number of side effects like 
diarrhoea, anorexia, fatigue and hair loss. Biological therapy includes use of interferons, 
interleukins, colony-stimulating factors, monoclonal antibodies, vaccines, gene therapy, and 
nonspecific immunomodulating agents and it is associated with flu-like symptoms including 
fever, chills, nausea, vomiting, appetite loss and increase in blood pressure. Radiation therapy 
can cause many side effects. Some are minor and diminish after therapy is stopped. The side 
effects include fatigue, skin inflammation in the treated areas, frequent or uncomfortable 
urination and rectal bleeding or irritation. Some side effects, however, are permanent. Bowel 
function may never become normal even after treatment is stopped. Impotence can occur up to 2 
years post-treatment in some patients. 
PHOTODYNAMIC THERAPY (PDT): 
Photodynamic therapy (PDT) is a treatment that uses a drug, called a photosensitizer or 
photosensitizing agent, and a particular type of light. When photosensitizers are exposed to a 
specific wavelength of light, they produce a form of oxygen that kills nearby cells(7,8,9).Each 
photosensitizer is activated by light of a specific wavelength(8,9). This wavelength determines 
how far the light can travel into the body(9,10). Thus, doctors use specific photosensitizers and 
wavelengths of light to treat different areas of the body with PDT. In the first step of PDT for 
cancer treatment, a photosensitizing agent is injected into the bloodstream. The agent is absorbed 
by cells all over the body but stays in cancer cells longer than it does in normal cells. 
Approximately 24 to 72 hours after injection7, when most of the agent has left normal cells but 
remains in cancer cells, the tumor is exposed to light. The photosensitizer in the tumor absorbs 
the light and produces an active form of oxygen that destroys nearby cancer cells(7,8,9). 
 
In addition to directly killing cancer cells, PDT appears to shrink or destroy tumors in two other 
ways(1,7,8,9). The photosensitizer can damage blood vessels in the tumor, thereby preventing the 
cancer from receiving necessary nutrients. In addition, PDT may activate the immune system to 
attack the tumor cells. The light used for PDT can come from a laser or light-emitting diodes 
(LEDs). Photosensitizers tend to build up in tumors and the activating light is focused on the 
tumor. As a result, damage to healthy tissue is minimal. However, PDT can cause burns, 
swelling, pain, and scarring in nearby healthy tissue9. Other side effects of PDT are related to the 
area that is treated. They can include coughing, trouble swallowing, stomach pain, painful 
breathing, or shortness of breath but these side effects are usually temporary. 
DNA PHOTONUCLEASES: 
DNA photonucleases or Photosensitizers (PS) are one of the key elements in PDT. After the 
approval of Photofrin® for PDT treatment, researchers from all over the world became actively 
involved in developing efficient compounds that can be used as photosensitizers. An ideal PS 
should fulfill the following requirements – 
a) It should be able to produce singlet oxygen efficiently because singlet oxygen and 
Norrish type II photochemical reaction is responsible for the majority of lesions 
generated during PDT. 
b) It should have high absorption coefficient. 
c) It should have no dark toxicity, minimal or absent skin photosensitivity, and should 
selectively accumulate in tumor tissue, in order to minimize skin sensitivity. 
d) The distribution of PS is important in PDT processes and is influenced by its chemical 
structure. It is particularly useful if PS is amphiphilic, which should facilitate the crossing 
of cell membranes. 
e) It should be stable and easy to dissolve in the injectable solvents. However, after 
administration, the compounds should show high tumor accumulation and rapid clearance 
from the system. 
f) It should be chemically pure and can be obtained in a short and high yielding synthetic 
route. 
Unfortunately, till date, no PS with all these ideal characteristics has been developed. 
 
 The DNA photonucleases get excited by light of a specific wavelength. This excitation 
uses either visible or near-infrared light. In photodynamic therapy, either the photo 
sensitizer molecule or the metabolic precursor of one is administered to the patient. The 
tissue to be treated is exposed to light suitable for exciting the photo sensitizer. Usually, 
the photo sensitizer is excited from a ground triplet state to an excited singlet state. It then 
undergoes intersystem crossing to a longer-lived excited triplet state. One of the few 
chemical species present in tissue with a ground triplet state is molecular oxygen. When 
the photo sensitizer and an oxygen molecule are in proximity, an energy transfer can take 
place that allows the photo sensitizer to relax to its ground singlet state, and create an 
excited singlet state oxygen molecule. The ROS, generated in PDT, damage the 
biomolecules, such as proteins and lipids, generating photoproducts. The mechanisms of 
ROS production can be type I, type II or both. The superoxide and other radicals species 
are generated with the type I mechanism by electron transfer from photo sensitizer, in the 
excited triplet state (T1), to ground-state oxygen (3O2). Singlet oxygen is generated with 
the type II mechanism by energy transfer from photo sensitizer T1 to 3O2(12,13). 
 
Type I radical mechanisms may work to a limited extent in the absence of oxygen based 
on the oxygen independent photosensitized cross-linking of DNA. However, this does not 
lead to cell photoinactivation11. Singlet oxygen is a very aggressive chemical species and 
will very rapidly react with any nearby biomolecules. Ultimately, these destructive 
reactions will kill cells through apoptosis or necrosis. 
 
 
MECHANISM OF CELL APOPTOSIS: 
 
The lifetime of photo sensitizer molecule in the triplet state in tissues is about 10µs11, 
which is long enough or the triplet state oxygen to form singlet oxygen, therefore is 
dependent on the oxygen concentration. It is therefore, realized that the oxygen 
dependency of PDT in cells is a crucial factor. Most normal tissues contain about 5% 
oxygen, which is supplied by blood circulation. The reason why they contain less than 
20% is simply respiration. But, the skin cells are often inflamed, well vascularized, and 
have slightly higher temperatures. Hence, the photo sensitizers has good selectivity for 
skin cancer cells11. PDT is unique in its ability to induce extensive apoptosis of a cancer 
cell. PDT causes acute inflammation, expression of heat-shock proteins, invasion and 
infiltration of the tumor by leukocytes, and might increase the presentation of tumor-
derived antigens to T cells. The hallmarks of apoptosis in animal cells include chromatin 
condensation, inter-nucleosomal DNA cleavage, cell fragmentation, and formation of 
apoptotic bodies. These bodies are removed by scavenging macrophages14. DNA 
fragmentation in particular has been used as an indication of apoptosis, and several 
simple assays have been used to assess the extent of DNA fragmentation in apoptotic 
cells. For example, agarose gel electrophoresis15 is used to demonstrate the ladder pattern 
of DNA which is generated by endonucleolytic cleavage of genomic DNA into 
nucleosomal size DNA of approximately 180 bases long (monomers) or oligonucleotides, 
which are multiples of 180 bases (oligomers)16. 
TYPES OF INORGANIC PHOTOSENSITIZERS BEING TESTED: 
Various metal compounds have been tested as possible photosensitizers for PDT17. Some of them 
are – 
A) Transition metal complexes: Metal complexes can act as prospective photosensitizers 
through both energy and electron transfer to oxygen molecules. Most of the studies on 
photogeneration of singlet oxygen involve polypyrrolic dyes and their metalloderivatives, 
but there is a significant number of other metal complexes capable of photosensitized 
singlet oxygen generation. A low energy triplet excited state of long lifetime is a 
prerequisite for this phenomenon. Mono and dinuclear RuII, CrIII, OsII, IrIII and PdII 
complexes with polypyridines, can be used as singlet oxygen photogenerators. 
B) Macrocyclic Photosensitizers modified by metal ions: Insertion of a metal ion to a 
polypyrrolic photo sensitizer can modify properties of its ground and excited state in such 
a way that not only photophysical and spectroscopic properties of the photo sensitizer 
will be modulated, but also its hydrophobicity, degree of aggregation, stability and 
consequently the route of the photo sensitizer transport into the cell and its further 
distribution. 
C) Semicondutors: Redox properties of excited semiconductor particles, especially TiO2 are 
responsible for high efficiency of ROS generation. TiO2 itself shows a very weak or no 
toxicity in vitro and in vivo. A significant cytotoxicity of TiO2 particles irradiated with 
UV light has been reported in the context of PDT applications. 
RUTHENIUM COMPLEXES AS PHOTOSENSITIZERS17: 
The drastic growth in research and development of DNA photonucleases based on Ruthenium 
complexes has been seen over the last decade. Various strategies have been used to improve the 
sequence selectivity of cleavage, which can arise from the preferential binding or activity at a 
certain site. Several mechanisms can be engaged in photoactivated DNA cleavage by Ruthenium 
complexes: 
a) Oxidation of the base by singlet oxygen formed via energy transfer from the triplet 
excited state of the photocleaver 
b) Direct electron transfer from the base to the excited state of the photocleaver 
c) Oxidation of the base by RuIII complex formed in situ by oxidative quenching of the 
triplet excited state of the corresponding complex 
There are three main properties that make ruthenium compounds well suited to target the cancer 
cells: 
(i) rate of ligand exchange 
(ii) the range of accessible oxidation states and 
(iii) the ability of ruthenium to mimic iron in binding to certain biological molecules. 
 
 
(i) Ligand Exchange18 
Many ruthenium complexes have been evaluated for clinical applications, particularly in the 
treatment of cancer, due in part, to Ru(II) and Ru(I1I) complexes having similar ligand exchange 
kinetics to those of Pt(II) complexes. Ligand exchange is an important determinant of biological 
activity, as very few metal drugs reach the biological target without being modified. Most 
undergo interactions with macromolecules, such as proteins, or small S-donor compounds and/or 
water. Some interactions are essential for inducing the desired therapeutic properties of the 
complexes. As the rate of ligand exchange is dependent on the concentration of the exchanging 
ligands in the surrounding solution, diseases that alter these concentrations in cells or in the 
surrounding tissues can have an effect on the activity of the drug.  
 
(ii) Oxidation State18 
Ruthenium is unique amongst the platinum group in that the oxidation states Ru(Il), Ru(III) 
and Ru (IV) are all accessible under physiological conditions. In these oxidation states the 
ruthenium centre is predominantly hexacoordinate with essentially octahedral geometry, and Ru 
(III) complexes tend to be more biologically inert than related Ru(II) and (IV) complexes. The 
redox potential of a complex can be modified by varying the ligands. In biological systems 
glutathione, ascorbate and single electron transfer proteins are able to reduce Ru(III) and Ru(IV), 
while molecular oxygen and cytochrome oxidase readily oxidize Ru(II). The redox potential of 
ruthenium compounds can be exploited to improve the effectiveness of drugs in the clinic. 
Cancer cells are known to have higher levels of glutathione and a lower pH than healthy tissues, 
creating a strongly reducing environment. If the active Ru(II) complex leaves the low oxygen 
environment, it may be converted back to Ru(III) by a variety of biological oxidants. Proteins 
that can catalyse the reduction of Ru(III) to Ru(II) include mitochondrial and microsomal single 
electron transfer proteins. The mitochondrial proteins are of particular interest in drug design as 
apoptosis, the desired mechanism for cell death, can be initiated in the mitochondria, as well as 
by other pathways, for instance, by the Fas/FasL pathway. Transmembrane electron transport 
systems can also reduce Ru(III) complexes outside of the cell and this is highly relevant to the 
mechanism of action of a ruthenium based drug in clinical use which has anticancer activity 
independent of cell entry. 
 
 
 
(iii) Iron Mimicking 
The low toxicity of ruthenium drugs is also believed to be due to the ability of ruthenium to 
mimic iron in binding to many biomolecules, including serum transferrin and albumin. These 
two proteins are used by mammals to solubilise and transport iron, thereby reducing its toxicity. 
Since rapidly dividing cells, for example microbially infected cells or cancer cells, have a greater 
requirement for iron, they increase the number of transferrin receptors located on their cell 
surfaces, thereby sequestering more of the circulating metal loaded transferrin. As a result, 
ruthenium drugs bind more selectively to the cancer cells and hence are less toxic to the 
surrounding normal cells. 
 
PHOTOCHEMISTRY OF RUTHENIUM COMPOUNDS19,20: 
Ruthenium compounds have been selected as photosensitizers because of their unique 
combination of chemical stability, redox properties, excited state reactivity, luminescence 
emission and excited state lifetime. Ru2+ is a d6 system and the polypyridine ligands are usually 
colourless molecules possessing the σ donor orbitals localized on the nitrogen atoms and π donor 
and π* acceptor orbitals more or less delocalized on aromatic rings. This opens up a range of new 
transitions, aside from the HOMO-LUMO transition observed in organic chromophores. This 
transition in inorganic photochemistry is called a ligand-field or ligand-ligand transition, as the 
excited state electron is located on the ligand.  Apart from this, because of the presence of the 
metal’s molecular orbitals, 3 other transitions are available:  
a)  d-d transition, where an electron is excited from a metal orbital to an unoccupied metal 
orbital. This is usually referred to as a metal centred (MC) transition  
b)  Transitions between the metal and the ligand. These can be either an electron excited 
from the ligand to the metal, called Ligand to Metal Charge Transfer (LMCT) or from the 
metal to the ligand (MLCT).  
c) Ligand – ligand transitions 
  
Because of the energy differences between the various types of transitions, ligand field 
transitions are usually in the near-UV region, charge transfer transitions are in the visible region. 
The resulting emission from charge-transfer states is often highly coloured. 
 
Ruthenium in oxidation state II is d6, and so as an octahedral complex its electrons are in the 
low-spin t2g6 configuration. Incident light at about 450 nm promotes one of these electrons to a 
ligand anti-bonding orbital, a metal to ligand charge transfer. Therefore, the S0 – S1 notation used 
in the Jablonski diagrams for excited state of Ruthenium compounds can be represented as 
1MLCT. Transfer to 3MLCT is efficient and so ruthenium complex’s photochemistry generally 
happens from here. From the Jablosnki diagram21, we can note that promotion of an electron 
from πM metal orbital to πL* ligand orbitals gives rise to metal to ligand charge transfer (MLCT) 
excited states whereas promotion of an electron from πM to σM* orbitals gives rise to metal 
centered (MC) excited states. Ligand centered (LC) excited states can be obtained by promoting 
an electron from πL to πL*. 
DNA BINDING: 
Deoxyribonucleic acid, DNA, is a molecule of great biological significance. The total DNA 
content of a cell is termed the ‘Genome’. The ‘Genome’ is unique to an organism, and is the 
information bank governing all life processes of the organism, DNA being the form in which this 
information is stored. Stretches of DNA called ‘genes’ have the extremely important function of 
coding for proteins. DNA is present in the body in the form of a double helix, where each strand 
is composed of a combination of four nucleotides, adenine (A), thymine (T), guanine (G) and 
cytosine (C) 22. The structure of DNA does not only exist as secondary structures such as double 
helices, but it can fold up on itself to form tertiary structures by supercoiling. Supercoiling 
allows for the compact packing of circular DNA. Circular DNA still exists as a double helix, but 
is considered a closed molecule because it is connected in a circular form. A superhelix is 
formed when the double helix is further coiled around an axis and crosses itself. Supercoiling not 
only allows for a compact form of DNA, but the extent of coiling also affects the DNA’s 
interactions with other molecules by determining the ability of the double helix to unwind.  
 
Supercoiling changes the shape of DNA. The benefit of a supercoiled DNA molecule is its 
compatibility. A nick is a discontinuity in a double stranded DNA molecule where there is no 
phosphodiester bond between adjacent nucleotides of one strand typically through damage or 
enzyme action. In comparison to a relaxed DNA molecule of the same length, a supercoiled 
DNA is more compact. This is reflected in experimentation as the supercoiled DNA moves faster 
than relaxed DNA. Therefore, the structural differences can be analyzed in techniques such as 
electrophoresis and centrifugation.  
DNA starts transcribing or replicating only when it receives a signal, which is often in the form 
of a regulatory protein binding to a particular region of the DNA. Thus, if the binding specificity 
and strength of this regulatory protein can be mimicked by a small molecule, then DNA function 
can be artificially modulated, inhibited or activated by binding this molecule instead of the 
protein. Thus, this synthetic/natural small molecule can act as a drug when activation or 
inhibition of DNA function is required to cure or control a disease. DNA inhibition would 
restrict protein synthesis, or replication, and could induce cell death. Though both these actions 
are possible, mostly DNA is targeted in an inhibitory mode, to destroy cells for antitumor and 
antibiotic action.  
Drugs bind to DNA both covalently as well as non-covalently. Covalent binding in DNA is 
irreversible and invariably leads to complete inhibition of DNA processes and subsequent cell 
death. Non-covalently bound drugs mostly fall under the following two classes:  
1. Minor groove binders- Minor groove binding drugs are usually crescent shaped, which 
complements the shape of the groove and facilitates binding by promoting Van der Waals 
interactions. Additionally, these drugs can form hydrogen bonds to bases, typically to N of 
adenine and O of thymine. Most minor groove binding drugs bind to A/T rich sequences.  
2. Intercalators- These contain planar heterocyclic groups which stack between adjacent DNA 
base pairs. The complex, among other factors, is thought to be stabilized by π-π stacking 
interactions between the drug and DNA bases. Intercalators introduce strong structural 
perturbations in DNA. 
AGAROSE GEL ELECTROPHORESIS: 
Agarose gel electrophoresis is the method used to acknowledge the damage done by the 
compound to the DNA. Nucleic acid molecules are separated by applying an electric field to 
move the negatively charged molecules through an agarose matrix. Shorter molecules move 
faster and migrate farther than longer ones because shorter molecules migrate more easily 
through the pores of the gel. This phenomenon is called sieving23. The most important factor is 
the length of the DNA molecule, smaller molecules travel faster. In this case, the supercoiled 
DNA moves faster than the nicked DNA due to its compact size and hence moves faster and to a 
longer distance. Increasing the agarose concentration of a gel reduces the migration speed and 
enables separation of smaller DNA molecules. The higher the voltage, the faster the DNA 
moves. But voltage is limited by the fact that it heats and ultimately causes the gel to melt. High 
voltages also decrease the resolution. The most common dye used to make DNA or RNA bands 
visible for agarose gel electrophoresis is ethidium bromide. It fluoresces under UV light when 
intercalated into DNA (or RNA). By running DNA through an EtBr-treated gel and visualizing it 
with UV light, any band containing more than ~20 ng DNA becomes distinctly visible. EtBr is a 
known mutagen, however, so safer alternatives are available.  
 
 
 
EXPERIMENTAL SECTION: 
The metal complexes under study should be nontoxic in the dark, absorb in the phototherapeutic 
window (600-1000 nm), have good DNA binding ability, able to cause photo-destruction of the 
cell. Ruthenium complexes are developed to imitate the action of cisplatin and show better 
activity, particularly on secondary tumors, and to reduce the host toxicity at active doses. In this 
research, we have tested the possibility of 3 ruthenium complexes showing good photodynamic 
activity. The 3 compounds tested were: 
a) Ru (tpy) (Br-pic) (dmso) (PF6) 
b) Ru (tpy) (mal) (dmso) 
c) Ru (tpy) (bpy) (CH3CN) (OTf)2  
Where, bpy- 2,2’- bipyridine  
            tpy- 2,2’,6,2’’- terpyridine 
            Otf- trifluoromethylsulfonate  
            Br-pic- 6- bromopicolinate  
                        mal- malonate 
These 3 compounds were tested for photophysical, photochemical and photobiological activity in 
order to understand their photo anti-cancer activity. 
 
A) SPECTROSCOPIC STUDIES: 
1) UV-VIS studies- All the three complexes under study are colored. It is evident that, they 
absorb in the visible region. UV-Visible absorption studies were performed on the 
solution of complexes in DMSO using ocean optics spectrophotometer. The results of 
wavelength maxima and molar extinction co-efficient were noted. 
2) Fluorescence studies: We performed the fluorescence studies using Ocean optics 
instrument USB 2000 for each compound. We did not observe any fluorescence in these 
compounds. 
 
B) DNA BINDING STUDIES: 
 DNA binding constant (Kb) is a proportionate measure of the binding ability of the complex 
with the DNA.  Binding constant, Kb is measured by the optical titration method as both the 
complexes tested are showing an increasing hypochromicity as calf thymus DNA is 
added24.Binding constant, Kb, is determined from the absorption changes during the DNA 
titration using the equation given below: 
(a-b)/(b-f) = (1/ Kb) x ( 1/[DNA]) + 1 
 
      ɛa = molar extinction coefficients for the absorption values at a given DNA concentration. 
ɛb = molar extinction coefficient for the absorption value of the complex fully bound to 
DNA. 
ɛf  = molar extinction coefficient for the absorption value of the complex free in solution 
   
The absorption and ɛb of the bound complexes was determined from the titration where 
further addition of DNA did not result in changes to the spectrum.  The binding constant for 
each molecule was determined by plotting (ɛa-ɛb)/(ɛb-ɛf) vs 1/[DNA], and Kb can be 
calculated as the reciprocal value of the slope.  
C) DNA PHOTOCLEAVAGE STUDIES: 
Gel electrophoresis is a technique used to separate the DNA fragments based on their size. 
First, the gel is prepared. Gels are made of Agarose, a sea weed extract similar to gelatin. The 
finished gel has a consistent appearance. This consistency offers resistance to the pieces of 
DNA as they try to move through the gel. Once the DNA samples are loaded onto the gel, an 
electric current is applied to the gel. The gel electrophoresis is based on the fact that the 
supercoiled DNA (uncut plasmid) will travel more rapidly than nicked DNA.  DNA is 
negatively charged due to the phosphate back bone. Thus DNA will move towards the 
positive electrode. 
1.5% Agarose gel was prepared by dissolving 0.75 g of Agarose in 50 ml of 2.5 X  Tris-
EDTA buffer, with the application of heat using a hot plate and a magnetic stirrer until the 
morbid solution became clear.  Ethidium bromide was added to the lukewarm solution in 
order to minimise the vapours of ethidium bromide. Ethidium bromide is mutagenic and 
should be handled with extreme care.  The DNA is visualised in the gel by the addition of 
ethidium bromide, which strongly binds to the DNA by intercalating between the bases 
.Buffers not only prevent ionic changes in the surroundings, but also provide ions to support 
conductivity. The use of high concentration of buffers (10X), may result in the melting of the 
gel due to the heat generated.   Slowly, the gel solution was poured into the gel plate without 
any air bubbles. Pouring the gel solution slowly into the gel plate reduces the air bubbles in 
the gel. Insert the gel comb at one end. It can be left to solidify for 15-20 minutes. 
The gel plate is then placed in the gel box, containing the buffer, and is connected to the 
power supply. Slowly remove the comb, so that the wells formed are well resolved. Samples 
are prepared by adding 5µl of plamid, 5µl of the complex and 2µl of the loading dye 
(bromophenol blue). Loading dye provides the density required for the sample to be easily 
loaded in to the well. Loading dyes are negatively charged in the neutral buffers and thus 
move in the same direction as the DNA, allowing us to monitor the progress of the gel. 
Bromophenol blue migrates at a rate equivalent to 200-400 base pair DNA. So, to look at 
fragments near this size ( ie., anything smaller than 600 bp), a different dye has to be used. 
Samples are then loaded in to the wells. The lid of the gel box is closed and voltage is 
applied. Stop the current supply when the loading dye has run ¾ the length of the gel. Carry 
the gel to a dark room to look under the UV light, which is carcinogenic. So, protective 
glasses, gloves and long sleeves should be used to avoid the contact of UV light with the 
skin.  
D) SINGLET OXYGEN STUDIES11: 
Singlet oxygen is the only electronically excited state of molecular oxygen. Used 
intentionally as a deleterious species in photodynamic therapy, its role as a biological 
messenger is being increasingly recognized.1O2 is mainly a product of photochemical 
reactions and its synthesis is eukaryotes is very limited confined to specific type of cells like 
eosinophils and macrophages. It exists in excited state for only a short time before losing its 
reactivity by transferring excess energy to other molecules or by returning to ground state. 
There are no anti-oxidant enzymes for elimination of singlet oxygen and chemical scavengers 
that intercept this oxygen metabolite must be present at high concentrations to be effective.  
The lifetime of 1O2 in water, which is only up to 4µs, limits the distance it can diffuse in cells 
and therefore, restricts its reactivity to the so-called “spatially resolved” reactions29. It readily 
reacts with DNA, lipids and proteins. Among amino acids residues, the most reactive with 
singlet oxygen are histidine, tryptophan,methionine, cysteine and tyrosine which form short 
lived endo- or hydroxy peroxides. In the presence of redox-reactive metal ions, these 
peroxides undergo decomposition with the formation of reactive radicals that can propagate 
chain reactions and oxidative damage to other biomolecules30,31. In the presence of Fe2+ or 
Cu2+, lipid peroxides can participate in Fenton reactions to produce oxy- (LO) and peroxy- 
(LOO) radicals capable of inducing DNA damage.  
Methods for 1O2 detection include EPR spectroscopy using spin traps32, phosphorescence at 
1270 nm33 and chemical trapping34. The current spread of fluorescence imaging techniques 
has lead to the development of a number of 1O2 fluorescent probes, such as trans-1-(2 -
methoxyvinyl)pyrene (MVP)35, dansyl-2,2,5,5-tetramethyl-2,5-dihydro-1H-pyrrole 
(DanePy)36,or fluorescein-based probes such as DMAX or DPAX37. Invitrogen/Molecular 
Probes has recently marketed a highly selective sensor for 1O2 without any appreciable 
response to hydroxyl radicals or superoxide, under the trade name Singlet Oxygen Sensor 
Green (SOSG) reagent®38. While the exact structure of SOSG has not been disclosed, its 
absorption spectrum resembles that of DMAX and it may therefore be assumed to contain a 
fluorescein bound to a dimethylanthracene derivative. 
The Singlet Oxygen Sensor Green reagent38 is highly selective for 1O2. Unlike other available 
fluorescent and chemiluminescent singlet oxygen detection reagents, it does not show any 
appreciable response to hydroxyl radical (.OH) or superoxide (.O2). This new singlet oxygen 
indicator initially exhibits weak blue fluorescence, with excitation peaks at 372 and 393 nm 
and emission peaks at 395 and 416 nm. In the presence of singlet oxygen, it emits a green 
fluorescence similar to that of fluorescein (excitation/emission maxima ~504/525 nm). The 
Singlet Oxygen Sensor Green reagent is supplied as a cell impermeant derivative. 
Coming to the method, 100 µg vial in 330 µL of methanol was used to make a stock solution 
of ~500 uM which produced green fluorescence at 525 nm. Then, compound solutions were 
irradiated for their time of irradiation respectively, then 40 uL of sensor green (10 uM) was 
added and immediately a fluorescent reading was taken. The fluorescent reading of only 
sensor green (no compound) and only compound without irradiation with sensor green were 
also taken to compare the results. 
E) CELL STUDIES: 
The human skin fibroblast cells obtained from the ATCC are cultured in 600 ml culture 
flasks using DMEM. The media is previously inoculated with Amphotericin B and 
Gentamycin. Media is changed at regular intervals (24,48,72 hours) until the cells are fully 
grown. Once the cells have fully grown, they are replated. The media is drained off.  The 
flasks are washed with PBS, at least thrice. Trypsin is added to the flasks, which suspends the 
cells struck to the walls of the flask. The flask are tapped and placed in the incubator for not 
more than 1 minute, as trypsin can digest the cells if placed in contact with them for a long 
time. To ensure that most of the cells remain suspended, observe under the microscope. The 
media is added immediately to inactivate the trypsin. The cells are then transferred to 60mm2 
petri dishes and allowed to grow until the plate is full.  
After the cells are fully grown in the petri dishes, they are transferred into 24 well plates and 
then, different concentrations of the drug are added. Two such plates are made for each 
compound tested – Dark and Light. One plate is not exposed to any light and immediately 
placed in the incubator after wrapping with sterilized aluminium foil which is labelled as 
Dark. The other plate is irradiated for a definite period of time for the drug to be 
photoactivated and hence show the activity; this plate is labelled as Light. Both the plates are 
incubated for 24 hrs and then the cell growth is observed. The cell growth in the wells is 
quantified by BCA protein assay. 
F) BCA PROTEIN ASSAY25,26,27: 
The Pierce BCA protein assay is a detergent compatible formulation based on bicinchoninic 
acid (BCA) for the colorimetric detection and quantitation of total protein. This method 
combines the well known reduction of Cu2+ to Cu1+ by protein in ana alkaline medium with 
the highly sensitive and selective colorimetric detection of the cuprous cation using a unique 
reagent containing bicinchoninic acid25. The purple colored reaction product of this assay is 
formed by the chelation of two molecules of BCA with one cuprous ion. This water soluble 
complex exhibits a strong absorbance at 562 nm that is nearly linear with increasing protein 
concentrations over broad working range (20-2000 µg/ml). The BCA method is not a true 
end-point method, i.e, the final color continues to develop. However, following incubation, 
the rate of continued color development is sufficiently slow to allow large numbers of 
samples to be assayed together. 
  
The macromolecular structure o protein, the number of peptide bonds and the presence o four 
particular amino acids (cysteine, cystine, tryptophan and tyrosine) are reported to be 
responsible for color formation with BCA28.Coming to the procedure for BCA protein assay, 
the cells are incubated for 24 hrs are they are exposed to the drug. Then the media is drained 
off and the cells are washed with PBS (twice). 100µl of surfactant (Tween 80) is added to 
each well, and incubated for 15 to 30 minutes. The cells are destructed by the surfactant. 
Then, BCA (bicinchoninic acid) assay reagent is added to each well and incubated (30 
minutes-1 hour), and then the absorbance reading can be noted using a plate reader at 562 
nm. 
RESULTS AND DISCUSSION 
A) SPECTROSCOPIC STUDIES: 
When UV- Visible studies were performed using the 75µM concentration of the 3 compounds, 
following results were obtained: 
 
From the above data, it can be elucidated that all the three compounds likely absorb light in the 
visible region. Molar extinction coefficient, , is the measure of how strongly a chemical 
absorbs particular wavelength of light. We can also observe that molar absorptivity co-efficient 
has considerably increased with the increase in the number of organic ligands. In case of 
compound 3, the solvent intended was CH3CN which showed an ε of 10,200 M-1cm-1. But, 
owing to the systemic toxicity of CH3CN, dmso was used as the solvent and the ε was slightly 
increased to 10414 M-1cm-1. Compounds 1, 2 and 3 show maximum absorbance at a wavelength 
of 446, 502 and 455 nm respectively. The compounds have to be irradiated at that particular 
wavelength to observe their photodynamic activity. 
S.NO Compound λmax in nm Molar absorptivity co-
efficient ( ε ) in M-1cm-1 
1) Ru (tpy) (Br-pic) (dmso) (PF6) 446 3529 
2) Ru (tpy) (mal) (dmso) 502 5134 
3) Ru (tpy) (bpy) (CH3CN) (OTf)2 455 10414 
B) DNA BINDING STUDIES: 
Binding constant, Kb was measured by the optical titration method as all the complexes tested 
were showing an increasing hypochromicity as calf thymus DNA is added.  
1) Ru(tpy)(Br-pic)(dmso)(PF6) was titrated with CT-DNA of concentration 800 µM until 
the absorbance became steady which meant saturation or fully bound DNA. From these 
values, a graph was plotted using (ɛa-ɛb)/(ɛb-ɛf) on Y-axis and 1/[DNA] on X-axis. 
The slope obtained was the value of 1/Kb which was found to be 9.4 x 10-6 and hence the 
DNA binding constant for this compound is 1.06 x 105/ M. 
 
2) Ru(tpy)(mal)(dmso) solution in DMSO was titrated with calf thymus DNA of 
concentration 250 µM until the absorbance starting at 0.789 steadily decreased and 
became steady at 0.715. From this data, a graph was plotted and the slope was calculated 
to be 1.98 x 10-6. Therefore, the drug DNA intrinsic binding constant was found to be 
5.05 x 105 /M. 
 3) Ru(tpy)(bpy)(CH3CN)(Otf)2 which was found to have the highest molar absorptivity co-
efficient among the three compounds showed better DNA binding when titrated with 
800 µM concentration of CT-DNA. From the graph, the slope value was calculated to be 
0.8 x 10-6 and hence the intrinsic binding constant was found to be 1.16 x 106 /M. 
 
The results of this experiment showed that all the 3 compounds bind very tightly to the DNA 
when compared to the standard ethidium bromide.  
C) DNA PHOTOCLEAVAGE STUDIES 
All the above results cumulatively indicate that these Ruthenium terpyridine complexes bind to 
CT-DNA in the groove mode. In order to show that these complexes could cause damage to DNA 
when photoactivated, agarose gel electrophoresis using pBR 322 DNA was performed using various 
concentrations of the compound in both dark and photo-activated forms. Photocleavage studies using 
the compound Ru(tpy)(Br-pic)(dmso)(PF6) produced the following results: 
 
                                                                                                                                                      
Here, Lane 1& 2-  Control dark & irradiated; Lane 3 & 4- 300µM dark & irradiated; Lane 5 & 6-
350µM dark & irradiated; Lane 7 & 8 – 400µM dark & irradiated. From these results, we can see 
that there is defintely a decrease in the distance travelled by the DNA as the concentration of the 
drug increases. This is a proof for the high DNA binding constant of the compound. Now coming 
to the photocleavage results, no photocleavage was observed and this only proves the singlet 
   1              2               3              4               5            6              7                8    
oxygen studies that this compound might not be showing any photodynamic activity or the 
pathway by which it acts is not by the destruction of DNA. 
When we performed the DNA photocleavage studies of Ru(tpy)(mal)(dmso) after irradiating for 
1.5 hrs at 502 nm, we could observe the photocleavage as below- 
 
In the photograph of the gel, Lane 1& 2-  Control dark & irradiated; Lane 3 & 4- 250µM dark & 
irradiated; Lane 5 & 6- 300µM dark & irradiated and Lane 7 & 8 – 350µM dark & irradiated.No 
DNA cleavage was observed for controls in which complex was absent (lane 1 and 2), With 
increasing concentration of the Ru (II) complex (lanes 3–8), the amount of Form I (supercoiled) 
of pBR322 DNA diminish gradually, whereas Form II (nicked) increases. The mechanism of the 
photocleavage activity can be tested by singlet oxygen studies. From this data, we can also 
observe the difference in the distance travelled as we increase the concentration and hence DNA 
migration studies to prove the good intrinsic binding of the compound. 
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Because of its very high intrinsic binding constant, Ru(tpy)(bpy)(CH3CN)(Otf)2 was of 
considerable interest. DNA cleavage was monitored by reaction of supercoiled circular pBR 322 
at 455 nm after irradiating for 1 hr. The following results were obtained –  
 
When circular plasmid DNA was subjected to electrophoresis, relatively fast migration was 
observed for the supercoiled (form I) as in Lanes 1 and 2. But, when the concentration of the 
compound was gradually increased, the supercoils were relaxed to generate a slower-moving 
open circular form or nicked DNA (form II). On comparing the photographs obtained for the 3 
compounds tested, we can see that the size of the plasmid varies though we used the same 
amount of plasmid for all the experiments. This shows that the compound has good intercalation 
with DNA. The difference in the distance travelled by the bands also proves the very high 
binding constant of this compound. 
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D) SINGLET OXYGEN STUDIES: 
The formation of 1O2 has been assessed by fluorescence detection by using Singlet oxygen 
sensor green (SOSG) as fluorescent probe. SOSG emits green fluorescence with an excitation 
and emission maxima at 504 and 525 nm respectively. In the course of our study, we have 
observed that the probe doesn’t have any fluorescence by itself even when irradiated. We already 
know that none of the compounds exhibit any fluorescence. We have also observed that all the 3 
compounds when added to the probe did not produce any fluorescence without irradiation. 
Finally, when the mixture was irradiated, we observed the following results – 
a) Ru(tpy)(Br-pic)(dmso)(PF6) did not show any fluorescence even when irradiated. This 
proves that the compound might not be having photodynamic activity. If it has any 
activity, it might not be due to the production of singlet oxygen. 
 
b) Ru(tpy)(mal)(dmso) showed an intensity of  938.99 at 525nm when irradiated together 
which was high compared to the readings probe (28.18) and their mixture (29.96). 
 
c) Ru(tpy)(bpy)(CH3CN)(Otf)2 on irradiation in the presence of SOSG produced a 
fluorescence intensity of 1213. 
 
The results above show that Ru(tpy)(mal)(dmso) and Ru(tpy)(bpy)(CH3CN)(Otf)2  can act as 
good 1O2 photosensitizers. 
E) CELL STUDIES AND BCA PROTEIN ASSAY:  
After the cell studies were performed, BCA protein assay was performed to quantify the cell 
viability. Based on the results obtained, LC 50 value was calculated for the compounds. This 
experiment was performed using Ru(tpy)(mal)(dmso) and Ru(tpy)(bpy)(CH3CN)(Otf)2 . The 
results of BCA protein assay, plotted as a graph to calculate the LC 50 are as follows – 
a) Ru(tpy)(mal)(dmso) 
 
From the graph, LC 50 value in the dark and light were found to be 1307 µM and 848 µM 
respectively. These results show that this compound is a good photo sensitizer and shows activity 
when irradiated with visible light. The main mechanism behind its action as we have seen can be 
attributed to the production of singlet oxygen.  Compared to the concentrations we used, the 
lethal concentration is very high almost 5 fold and hence can be considered to have a very good 
potential. Its effect on cancer cells has to be tested to confirm its clinical use. 
 
b) Ru(tpy)(bpy)(CH3CN)(Otf)2  
 
As we can see, the results were convincing that this compound has good DNA photocleavage 
activity at a low concentration. The LC 50 value in the dark and light were found to be 1244 µM 
and 488 µM respectively. This shows that though the compound might have good DNA binding 
and photocleavage activity, it might still be toxic when used clinically. The result of its effect on 
cancer cells has yet to be tested. 
 
METAL COMPLEX LC 50 (DARK) LC 50 (LIGHT) 
Ru(tpy)(mal)(dmso) 1307 µM 848 µM 
Ru(tpy)(bpy)(CH3CN)(Otf)2 1244 µM 488 µM 
 
CONCLUSION: 
Octahedral Ruthenium- terpyridine complexes were employed to improve the sequence selectivity of 
cleavage which can arise from preferential binding at a certain site for treatment of cancer. All the three 
compounds showed good absorbance in the visible region and good DNA binding capacity. But, only 
Ru(tpy)(mal)(dmso) and Ru(tpy)(bpy)(CH3CN)(Otf)2 could be proven to be good  potential 
photosensitizers owing to the consistent results observed in DNA photocleavage studies, Singlet 
oxygen studies and the Cell studies using Human skin Fibroblasts.  
 
FUTURE STUDIES: 
In the future, we would like to continue the research for testing the compounds on cancer cells 
for cytotoxicity and photocytotoxicity.  
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